Document is current
Any future updates will be listed below
-
Authors
Cohen, Stanley B
Tanaka, Yoshiya https://orcid.org/0000-0002-0807-7139
Mariette, Xavier https://orcid.org/0000-0002-4244-5417
Curtis, Jeffrey R https://orcid.org/0000-0002-8907-8976
Lee, Eun Bong https://orcid.org/0000-0003-0703-1208
Nash, Peter https://orcid.org/0000-0002-2571-788X
Winthrop, Kevin L https://orcid.org/0000-0002-3892-6947
Charles-Schoeman, Christina
Wang, Lisy https://orcid.org/0000-0003-1096-0868
Chen, Connie
Kwok, Kenneth
Biswas, Pinaki
Shapiro, Andrea
Madsen, Ann
Wollenhaupt, Jürgen
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01484561 at ClinicalTrials.govnct00147498 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00413660 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00550446 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
SAT0111 Efficacy of tofacitinib in patients with moderate to severe rheumatoid arthritis by baseline c-reactive protein levels and erythrocyte sedimentation rates
https://doi.org/10.1136/annrheumdis-2018-eular.2676
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00603512 at ClinicalTrials.govDocuments that mention this clinical trial
AB0449 PAIN REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB MONOTHERAPY WITH OR WITHOUT PAIN MEDICATION: A POST HOC ANALYSIS OF POOLED DATA FROM PHASE 2, PHASE 3 AND PHASE 3B/4 STUDIES
https://doi.org/10.1136/annrheumdis-2019-eular.416
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
SAT0139 AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.1432
THU0033 RNA PROFILING OF HEALTHY AND RHEUMATOID ARTHRITIS SUBJECTS TREATED WITH TOFACITINIB MONOTHERAPY
https://doi.org/10.1136/annrheumdis-2019-eular.1928
Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic diseasemodifying antirheumatic drugs
https://doi.org/10.1136/annrheumdis-2014-207178corr1
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
https://doi.org/10.1136/annrheumdis-2020-218992
SAT0111 Efficacy of tofacitinib in patients with moderate to severe rheumatoid arthritis by baseline c-reactive protein levels and erythrocyte sedimentation rates
https://doi.org/10.1136/annrheumdis-2018-eular.2676
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00687193 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
THU0191 Effects of tofacitinib, an oral janus kinase inhibitor, on patient-reported outcomes in japanese patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1402
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
SAT0111 Efficacy of tofacitinib in patients with moderate to severe rheumatoid arthritis by baseline c-reactive protein levels and erythrocyte sedimentation rates
https://doi.org/10.1136/annrheumdis-2018-eular.2676
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct01164579 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
THU0191 Effects of tofacitinib, an oral janus kinase inhibitor, on patient-reported outcomes in japanese patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1402
AB0072 BIOMARKER CHANGES FOR PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB WITH METHOTREXATE OR GLUCOCORTICOIDS VS TOFACITINIB MONOTHERAPY
https://doi.org/10.1136/annrheumdis-2019-eular.774
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
SAT0111 Efficacy of tofacitinib in patients with moderate to severe rheumatoid arthritis by baseline c-reactive protein levels and erythrocyte sedimentation rates
https://doi.org/10.1136/annrheumdis-2018-eular.2676
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00976599 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
POS0443 EXPLORING NOVEL TENOSYNOVITIS AND COMBINED INFLAMMATION IMAGING OUTCOMES: RESULTS FROM A RANDOMISED CONTROLLED TRIAL IN EARLY RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.364
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques
https://doi.org/10.1136/annrheumdis-2015-208267
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct01059864 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2014-206028
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct01359150 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct02147587 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2014-207191
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00960440 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
OP0230 The effectiveness of zoster vaccine in RA patients subsequently treated with TOFACITINIB
https://doi.org/10.1136/annrheumdis-2017-eular.2437
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib
https://doi.org/10.1136/annrheumdis-2019-216566
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00847613 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
https://doi.org/10.1016/s0140-6736(12)61424-x
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
https://doi.org/10.1007/s40744-021-00405-w
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
https://doi.org/10.1007/s40744-023-00612-7
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis (Results)
https://doi.org/10.1136/rmdopen-2022-002478
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2019-001042
SAT0127 The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index
https://doi.org/10.1136/annrheumdis-2018-eular.1284
OP0052 THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS WITH COMPLETE CONTROL OF INFLAMMATION
https://doi.org/10.1136/annrheumdis-2022-eular.58
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
AB0436 Comparison of tofacitinib efficacy in patients with moderate vs severe rheumatoid arthritis: pooled analysis of phase 3 studies
https://doi.org/10.1136/annrheumdis-2017-eular.1846
SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2018-eular.3247
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies
https://doi.org/10.1136/rmdopen-2021-002103
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
https://doi.org/10.1136/rmdopen-2018-000742
AB0454 FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY
https://doi.org/10.1136/annrheumdis-2019-eular.418
SAT0111 Efficacy of tofacitinib in patients with moderate to severe rheumatoid arthritis by baseline c-reactive protein levels and erythrocyte sedimentation rates
https://doi.org/10.1136/annrheumdis-2018-eular.2676
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
AB0247 ANALYSIS OF THE IMPACT OF TOFACITINIB TREATMENT ON WEIGHT IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.360
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00814307 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
https://doi.org/10.1007/s40744-021-00405-w
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
https://doi.org/10.1007/s40744-023-00612-7
POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.359
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis (Results)
https://doi.org/10.1136/rmdopen-2022-002478
SAT0217 Identification of distinct disease activity trajectories in patients with rheumatoid arthritis receiving tofacitinib over 12 months
https://doi.org/10.1136/annrheumdis-2018-eular.1281
THU0191 Effects of tofacitinib, an oral janus kinase inhibitor, on patient-reported outcomes in japanese patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1402
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2019-001042
AB0072 BIOMARKER CHANGES FOR PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB WITH METHOTREXATE OR GLUCOCORTICOIDS VS TOFACITINIB MONOTHERAPY
https://doi.org/10.1136/annrheumdis-2019-eular.774
SAT0127 The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index
https://doi.org/10.1136/annrheumdis-2018-eular.1284
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
AB0436 Comparison of tofacitinib efficacy in patients with moderate vs severe rheumatoid arthritis: pooled analysis of phase 3 studies
https://doi.org/10.1136/annrheumdis-2017-eular.1846
SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2018-eular.3247
AB0417 EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO DURATION OF PRIOR CSDMARD TREATMENT AND NUMBER OF PRIOR CSDMARDS: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.417
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies
https://doi.org/10.1136/rmdopen-2021-002103
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
https://doi.org/10.1136/rmdopen-2018-000742
AB0454 FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY
https://doi.org/10.1136/annrheumdis-2019-eular.418
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
https://doi.org/10.1136/bmjopen-2023-082366
SAT0111 Efficacy of tofacitinib in patients with moderate to severe rheumatoid arthritis by baseline c-reactive protein levels and erythrocyte sedimentation rates
https://doi.org/10.1136/annrheumdis-2018-eular.2676
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
AB0247 ANALYSIS OF THE IMPACT OF TOFACITINIB TREATMENT ON WEIGHT IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.360
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00856544 at ClinicalTrials.govDocuments that mention this clinical trial
AB0449 PAIN REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB MONOTHERAPY WITH OR WITHOUT PAIN MEDICATION: A POST HOC ANALYSIS OF POOLED DATA FROM PHASE 2, PHASE 3 AND PHASE 3B/4 STUDIES
https://doi.org/10.1136/annrheumdis-2019-eular.416
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
THU0186 Magnitude and duration of early response with tofacitinib: post-hoc analysis of two phase 3, placebo-controlled studies
https://doi.org/10.1136/annrheumdis-2017-eular.1556
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
https://doi.org/10.1007/s40744-021-00405-w
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
https://doi.org/10.1007/s40744-023-00612-7
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis (Results)
https://doi.org/10.1136/rmdopen-2022-002478
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2019-001042
SAT0127 The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index
https://doi.org/10.1136/annrheumdis-2018-eular.1284
OP0052 THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS WITH COMPLETE CONTROL OF INFLAMMATION
https://doi.org/10.1136/annrheumdis-2022-eular.58
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
AB0436 Comparison of tofacitinib efficacy in patients with moderate vs severe rheumatoid arthritis: pooled analysis of phase 3 studies
https://doi.org/10.1136/annrheumdis-2017-eular.1846
AB0417 EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO DURATION OF PRIOR CSDMARD TREATMENT AND NUMBER OF PRIOR CSDMARDS: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.417
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies
https://doi.org/10.1136/rmdopen-2021-002103
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
https://doi.org/10.1136/rmdopen-2018-000742
AB0454 FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY
https://doi.org/10.1136/annrheumdis-2019-eular.418
SAT0111 Efficacy of tofacitinib in patients with moderate to severe rheumatoid arthritis by baseline c-reactive protein levels and erythrocyte sedimentation rates
https://doi.org/10.1136/annrheumdis-2018-eular.2676
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
AB0247 ANALYSIS OF THE IMPACT OF TOFACITINIB TREATMENT ON WEIGHT IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.360
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00853385 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
THU0186 Magnitude and duration of early response with tofacitinib: post-hoc analysis of two phase 3, placebo-controlled studies
https://doi.org/10.1136/annrheumdis-2017-eular.1556
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
https://doi.org/10.1007/s40744-021-00405-w
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
https://doi.org/10.1007/s40744-023-00612-7
POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.359
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis (Results)
https://doi.org/10.1136/rmdopen-2022-002478
SAT0217 Identification of distinct disease activity trajectories in patients with rheumatoid arthritis receiving tofacitinib over 12 months
https://doi.org/10.1136/annrheumdis-2018-eular.1281
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2019-001042
SAT0127 The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index
https://doi.org/10.1136/annrheumdis-2018-eular.1284
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
THU0215 Effects of tofacitinib on patient-reported outcomes in a phase 3 study of chinese patients with active rheumatoid arthritis and an inadequate response to dmards
https://doi.org/10.1136/annrheumdis-2017-eular.2273
AB0436 Comparison of tofacitinib efficacy in patients with moderate vs severe rheumatoid arthritis: pooled analysis of phase 3 studies
https://doi.org/10.1136/annrheumdis-2017-eular.1846
SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2018-eular.3247
AB0417 EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO DURATION OF PRIOR CSDMARD TREATMENT AND NUMBER OF PRIOR CSDMARDS: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.417
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies
https://doi.org/10.1136/rmdopen-2021-002103
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
https://doi.org/10.1136/rmdopen-2018-000742
AB0454 FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY
https://doi.org/10.1136/annrheumdis-2019-eular.418
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
https://doi.org/10.1136/bmjopen-2023-082366
SAT0111 Efficacy of tofacitinib in patients with moderate to severe rheumatoid arthritis by baseline c-reactive protein levels and erythrocyte sedimentation rates
https://doi.org/10.1136/annrheumdis-2018-eular.2676
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
AB0247 ANALYSIS OF THE IMPACT OF TOFACITINIB TREATMENT ON WEIGHT IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.360
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct01039688 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
https://doi.org/10.1007/s40744-021-00405-w
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
https://doi.org/10.1007/s40744-023-00612-7
POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.359
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis (Results)
https://doi.org/10.1136/rmdopen-2022-002478
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis
https://doi.org/10.1007/s12325-021-01930-4
SAT0217 Identification of distinct disease activity trajectories in patients with rheumatoid arthritis receiving tofacitinib over 12 months
https://doi.org/10.1136/annrheumdis-2018-eular.1281
Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan
https://doi.org/10.1080/13696998.2019.1606813
Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
https://doi.org/10.1136/rmdopen-2019-001042
SAT0127 The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index
https://doi.org/10.1136/annrheumdis-2018-eular.1284
FRI0144 JOINT-SPECIFIC RESPONSES TO TOFACITINIB AND ADALIMUMAB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STANDARD AND ORAL STRATEGY
https://doi.org/10.1136/annrheumdis-2019-eular.1196
OP0052 THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS WITH COMPLETE CONTROL OF INFLAMMATION
https://doi.org/10.1136/annrheumdis-2022-eular.58
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
AB0436 Comparison of tofacitinib efficacy in patients with moderate vs severe rheumatoid arthritis: pooled analysis of phase 3 studies
https://doi.org/10.1136/annrheumdis-2017-eular.1846
SAT0221 Effect of tofacitinib on reducing pain in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
https://doi.org/10.1136/annrheumdis-2018-eular.3247
SAT0139 AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.1432
AB0417 EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO DURATION OF PRIOR CSDMARD TREATMENT AND NUMBER OF PRIOR CSDMARDS: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.417
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies
https://doi.org/10.1136/rmdopen-2021-002103
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib
https://doi.org/10.1136/rmdopen-2018-000742
AB0454 FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY
https://doi.org/10.1136/annrheumdis-2019-eular.418
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
https://doi.org/10.1136/annrheumdis-2020-218992
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
https://doi.org/10.1136/bmjopen-2023-082366
SAT0111 Efficacy of tofacitinib in patients with moderate to severe rheumatoid arthritis by baseline c-reactive protein levels and erythrocyte sedimentation rates
https://doi.org/10.1136/annrheumdis-2018-eular.2676
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
AB0247 ANALYSIS OF THE IMPACT OF TOFACITINIB TREATMENT ON WEIGHT IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.360
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct02187055 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis (Results)
https://doi.org/10.1136/rmdopen-2022-002478
Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2015-000232
AB0072 BIOMARKER CHANGES FOR PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB WITH METHOTREXATE OR GLUCOCORTICOIDS VS TOFACITINIB MONOTHERAPY
https://doi.org/10.1136/annrheumdis-2019-eular.774
SAT0127 The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index
https://doi.org/10.1136/annrheumdis-2018-eular.1284
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison
https://doi.org/10.1136/rmdopen-2019-001131
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2016-000262
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
AB0436 Comparison of tofacitinib efficacy in patients with moderate vs severe rheumatoid arthritis: pooled analysis of phase 3 studies
https://doi.org/10.1136/annrheumdis-2017-eular.1846
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies
https://doi.org/10.1136/rmdopen-2021-002103
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
https://doi.org/10.1136/rmdopen-2016-000308
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
AB0247 ANALYSIS OF THE IMPACT OF TOFACITINIB TREATMENT ON WEIGHT IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.360
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00413699 at ClinicalTrials.govDocuments that mention this clinical trial
THU0193 EFFICACY OF TOFACITINIB MONOTHERAPY, TOFACITINIB WITH METHOTREXATE AND ADALIMUMAB WITH METHOTREXATE IN PATIENTS WITH EARLY (≤2 YEARS) VS ESTABLISHED (>2 YEARS) RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STRATEGY
https://doi.org/10.1136/annrheumdis-2019-eular.587
AB0449 PAIN REDUCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB MONOTHERAPY WITH OR WITHOUT PAIN MEDICATION: A POST HOC ANALYSIS OF POOLED DATA FROM PHASE 2, PHASE 3 AND PHASE 3B/4 STUDIES
https://doi.org/10.1136/annrheumdis-2019-eular.416
Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis
https://doi.org/10.1007/s40744-025-00823-0
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib
https://doi.org/10.1007/s40744-021-00405-w
Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials
https://doi.org/10.1007/s40744-023-00612-7
LB0003 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: results from oral strategy, a phase 3b/4 randomised trial
https://doi.org/10.1136/annrheumdis-2017-eular.7113
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis (Results)
https://doi.org/10.1136/rmdopen-2022-002478
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
https://doi.org/10.1136/rmdopen-2019-001040
SAT0220 Evaluation of live zoster vaccine in a subset of patients with rheumatoid arthritis treated with tofacitinib with or without methotrexate, and adalimumab with methotrexate: results from a phase 3b/4 randomised trial
https://doi.org/10.1136/annrheumdis-2018-eular.1469
FRI0144 JOINT-SPECIFIC RESPONSES TO TOFACITINIB AND ADALIMUMAB IN RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF DATA FROM ORAL STANDARD AND ORAL STRATEGY
https://doi.org/10.1136/annrheumdis-2019-eular.1196
SAT0252 Clinical and functional response to tofacitinib and adalimumab in patients with rheumatoid arthritis: probability plot analysis of results from the oral strategy trial
https://doi.org/10.1136/annrheumdis-2018-eular.3735
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
https://doi.org/10.1136/rmdopen-2016-000262
OP0052 THE EFFECT OF TOFACITINIB ON RESIDUAL PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PSORIATIC ARTHRITIS WITH COMPLETE CONTROL OF INFLAMMATION
https://doi.org/10.1136/annrheumdis-2022-eular.58
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
SAT0139 AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.1432
AB0417 EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO DURATION OF PRIOR CSDMARD TREATMENT AND NUMBER OF PRIOR CSDMARDS: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 TRIALS
https://doi.org/10.1136/annrheumdis-2019-eular.417
SAT0256 Tofacitinib with and without methotrexate versus adalimumab with methotrexate for the treatment of rheumatoid arthritis: patient-reported outcomes from a phase 3b/4 randomised trial
https://doi.org/10.1136/annrheumdis-2018-eular.1312
AB0454 FREQUENCY AND DURATION OF EARLY NON-SERIOUS ADVERSE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TOFACITINIB 5 MG TWICE DAILY AS MONOTHERAPY AND COMBINATION THERAPY
https://doi.org/10.1136/annrheumdis-2019-eular.418
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
https://doi.org/10.1136/annrheumdis-2020-218992
SAT0247 Impact of glucocorticoids on efficacy and safety of tofacitinib with and without methotrexate and adalimumab with methotrexate for rheumatoid arthritis: results from a phase 3b/4 randomised trial
https://doi.org/10.1136/annrheumdis-2018-eular.1533
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
AB0247 ANALYSIS OF THE IMPACT OF TOFACITINIB TREATMENT ON WEIGHT IN PATIENTS WITH RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2021-eular.360
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00661661 at ClinicalTrials.govDocuments that mention this clinical trial
SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years
https://doi.org/10.1136/annrheumdis-2018-eular.1733
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.359
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2014-207191
OP0230 The effectiveness of zoster vaccine in RA patients subsequently treated with TOFACITINIB
https://doi.org/10.1136/annrheumdis-2017-eular.2437
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib
https://doi.org/10.1136/annrheumdis-2019-216566
THU0197 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 8 years
https://doi.org/10.1136/annrheumdis-2017-eular.1166
OP0033 Effect of a step-up or step-down in tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis in long-term extension studies
https://doi.org/10.1136/annrheumdis-2018-eular.3110
OP0037 Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: analysis of data from open-label long-term extension studies
https://doi.org/10.1136/annrheumdis-2018-eular.3755
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2014-206028
THU0193 Reestablishment of efficacy of tofacitinib, an oral janus kinase inhibitor, in rheumatoid arthritis patients after temporary discontinuation
https://doi.org/10.1136/annrheumdis-2017-eular.2375
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
https://doi.org/10.1136/bmjopen-2023-082366
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
https://doi.org/10.1136/bmjopen-2024-096952
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies (Pre-results)
https://doi.org/10.1136/rmdopen-2017-000491
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct02092467 at ClinicalTrials.govDocuments that mention this clinical trial
SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years
https://doi.org/10.1136/annrheumdis-2018-eular.1733
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.359
THU0191 Effects of tofacitinib, an oral janus kinase inhibitor, on patient-reported outcomes in japanese patients with rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.1402
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
THU0197 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 8 years
https://doi.org/10.1136/annrheumdis-2017-eular.1166
OP0033 Effect of a step-up or step-down in tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis in long-term extension studies
https://doi.org/10.1136/annrheumdis-2018-eular.3110
OP0037 Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: analysis of data from open-label long-term extension studies
https://doi.org/10.1136/annrheumdis-2018-eular.3755
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
https://doi.org/10.1136/bmjopen-2023-082366
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
https://doi.org/10.1136/bmjopen-2024-096952
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies (Results)
https://doi.org/10.1136/rmdopen-2017-000491
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
nct00413699 at ClinicalTrials.govDocuments that mention this clinical trial
Waiting for JAK inhibitor safety data
https://doi.org/10.1136/rmdopen-2022-002236
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
https://doi.org/10.1136/annrheumdis-2019-216761
Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance
https://doi.org/10.1007/s40744-024-00693-y
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
https://doi.org/10.1136/annrheumdis-2019-216655
RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
https://doi.org/10.1136/rmdopen-2021-001565
POS0519 RELATIONSHIP BETWEEN DISEASE ACTIVITY AND MAJOR ADVERSE EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS ON TOFACITINIB OR TNF INHIBITORS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
https://doi.org/10.1136/annrheumdis-2022-eular.1238
POS0239 RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3b/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS
https://doi.org/10.1136/annrheumdis-2022-eular.1016
POS0674 RISK FACTORS FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS AGED ≥50 YEARS WITH RHEUMATOID ARTHRITIS AND ≥1 ADDITIONAL CARDIOVASCULAR RISK FACTOR: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
https://doi.org/10.1136/annrheumdis-2022-eular.1234
Correspondence on ‘EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update‘
https://doi.org/10.1136/annrheumdis-2020-218573
Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
https://doi.org/10.1136/annrheumdis-2021-221276
POS0824 CARDIOVASCULAR (CV) AND MALIGNANCY EVENTS IN THE FILGOTINIB (FIL) RHEUMATOID ARTHRITIS (RA) CLINICAL DEVELOPMENT PROGRAM UP TO 8.3 YEARS
https://doi.org/10.1136/annrheumdis-2023-eular.1425
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
POS0520 ASSOCIATION BETWEEN BASELINE STATIN TREATMENT AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF ORAL SURVEILLANCE
https://doi.org/10.1136/annrheumdis-2022-eular.1255
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance (Results)
https://doi.org/10.1136/ard-2022-222259
SAT0139 AGE-BASED (<65 VS ≥65 YEARS) INCIDENCE OF INFECTIONS AND SERIOUS INFECTIONS IN TOFACITINIB-, ADALIMUMAB- AND PLACEBO-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS: A POST HOC ANALYSIS OF PHASE 2, PHASE 3 AND PHASE 3B/4 TOFACITINIB STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.1432
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
https://doi.org/10.1136/rmdopen-2023-003912
OP0269 BIOMARKERS TO PREDICT RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS
https://doi.org/10.1136/annrheumdis-2022-eular.787
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222405
Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
https://doi.org/10.1136/rmdopen-2021-001595
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry
https://doi.org/10.1136/annrheumdis-2020-218992
AB0530 A PRACTICAL FRAMEWORK FOR INDIVIDUALIZED BENEFIT/RISK ASSESSMENT AND CLINICAL DECISION-MAKING ON TREATMENT WITH TOFACITINIB
https://doi.org/10.1136/annrheumdis-2024-eular.2850
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
https://doi.org/10.1136/bmjopen-2023-082366
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
POS0827 CLINICAL OUTCOMES OF PATIENTS WITH RHEUMATOID ARTHRITIS WHO DISCONTINUED TOFACITINIB OR TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM ORAL SURVEILLANCE
https://doi.org/10.1136/annrheumdis-2023-eular.2670
OP0043 IMPACT OF CARDIOVASCULAR COMORBIDITIES ON EFFICACY OF TOFACITINIB VS TNFI IN RHEUMATOID ARTHRITIS
https://doi.org/10.1136/annrheumdis-2023-eular.2688
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors
https://doi.org/10.1136/rmdopen-2022-002571
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
https://doi.org/10.1136/annrheumdis-2021-221915
nct00413699 at ClinicalTrials.govDocuments that mention this clinical trial
SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years
https://doi.org/10.1136/annrheumdis-2018-eular.1733
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.359
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2014-207191
OP0230 The effectiveness of zoster vaccine in RA patients subsequently treated with TOFACITINIB
https://doi.org/10.1136/annrheumdis-2017-eular.2437
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib
https://doi.org/10.1136/annrheumdis-2019-216566
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
THU0197 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 8 years
https://doi.org/10.1136/annrheumdis-2017-eular.1166
OP0033 Effect of a step-up or step-down in tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis in long-term extension studies
https://doi.org/10.1136/annrheumdis-2018-eular.3110
OP0037 Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: analysis of data from open-label long-term extension studies
https://doi.org/10.1136/annrheumdis-2018-eular.3755
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2014-206028
THU0193 Reestablishment of efficacy of tofacitinib, an oral janus kinase inhibitor, in rheumatoid arthritis patients after temporary discontinuation
https://doi.org/10.1136/annrheumdis-2017-eular.2375
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
https://doi.org/10.1136/bmjopen-2023-082366
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
https://doi.org/10.1136/bmjopen-2024-096952
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies (Pre-results)
https://doi.org/10.1136/rmdopen-2017-000491
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
Documents that mention this clinical trial
SAT0234 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 9 years
https://doi.org/10.1136/annrheumdis-2018-eular.1733
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
https://doi.org/10.1136/rmdopen-2020-001395
POS0652 SEX DIFFERENCES IN THE EFFICACY AND SAFETY OF TOFACITINIB IN RHEUMATOID ARTHRITIS PATIENTS: A POST HOC ANALYSIS OF PHASE 3 AND LONG-TERM EXTENSION TRIALS
https://doi.org/10.1136/annrheumdis-2021-eular.359
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2014-207191
OP0230 The effectiveness of zoster vaccine in RA patients subsequently treated with TOFACITINIB
https://doi.org/10.1136/annrheumdis-2017-eular.2437
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib
https://doi.org/10.1136/annrheumdis-2019-216566
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme
https://doi.org/10.1136/ard-2022-223406
THU0197 Tofacitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension studies over 8 years
https://doi.org/10.1136/annrheumdis-2017-eular.1166
OP0033 Effect of a step-up or step-down in tofacitinib dose on efficacy and safety in patients with rheumatoid arthritis in long-term extension studies
https://doi.org/10.1136/annrheumdis-2018-eular.3110
OP0037 Efficacy of tofacitinib after temporary discontinuation in patients with rheumatoid arthritis: analysis of data from open-label long-term extension studies
https://doi.org/10.1136/annrheumdis-2018-eular.3755
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2014-206028
THU0193 Reestablishment of efficacy of tofacitinib, an oral janus kinase inhibitor, in rheumatoid arthritis patients after temporary discontinuation
https://doi.org/10.1136/annrheumdis-2017-eular.2375
Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials
https://doi.org/10.1136/bmjopen-2023-082366
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance
https://doi.org/10.1136/ard-2022-223715
Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
https://doi.org/10.1007/s40744-022-00507-z
Tofacitinib in rheumatoid arthritis: a German real-world study with focus on treatment changes, effectiveness and patient-reported outcomes (ESCALATE-RA)
https://doi.org/10.1136/bmjopen-2024-096952
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies (Pre-results)
https://doi.org/10.1136/rmdopen-2017-000491
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial
https://doi.org/10.1136/ard-2022-222543
- License Information
